Heidelberg Pharma AG

Research Heidelberg Pharma AG (HPHA) on Bullrun: market cap EUR 124.45M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerHPHA
• ExchangeXETRA
• CountryGermany
• SectorHealthcare
• IndustryBiotechnology
• CurrencyEUR
• Market capEUR 124.45M
• Financial periodQ4 2025
• RevenueEUR 21.44K
• Net income-EUR 21.23M
• Free cash flow-EUR 6.74M
• Gross margin-321.4%

Valuation Snapshot

latest market cap is EUR 124.45M.

About Heidelberg Pharma AG

Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, Europe, China, the United States, and internationally. The company's lead product candidates include HDP-101, an anti-BCMA antibody, which in the Phase I/IIa study for the treatment of relapsed or refractory multiple myeloma. It also develops HDP-102, an antibody and the compound Amanitin, which has completed preclinical development for the treatment of non-Hodgkin lymphoma;

Frequently asked questions

What is Heidelberg Pharma AG's market cap?

Heidelberg Pharma AG's market capitalization is EUR 124.45M.

What does Heidelberg Pharma AG do?

Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, Europe, China, the United States, and internationally.